TBPH - Theravance Biopharma, Inc.
| Previous Close | 26.91 |
| Open | 26.89 |
| Bid | 26.940 x 800 |
| Ask | 27.010 x 800 |
| Day's Range | 26.40 - 27.49 |
| 52 Week Range | 21.27 - 35.48 |
| Volume | 29,209 |
| Avg. Volume | 177,090 |
| Market Cap | 1.486B |
| Beta (3Y Monthly) | 1.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.710 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.86 |
- PR Newswire•21 hours ago
/C O R R E C T I O N -- Theravance Biopharma, Inc./
In the news release, Theravance Biopharma to Report Fourth Quarter and Full Year 2018 Financial Results on February 26, issued 19-Feb-2019 by Theravance Biopharma, Inc. over PR Newswire, we are advised by the company that date in the second paragraph, first sentence, should read "February 26, 2019" rather than "November 6, 2018" as originally issued inadvertently. DUBLIN, Feb. 19, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2018 and provide a business update after market close on Tuesday, February 26, 2019. An accompanying conference call will be held at 5:00 pm ET on February 26, 2019. To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 8086288.
- Zacks•yesterday
Will Leasing Support SBA Communications' (SBAC) Q4 Earnings?
Solid domestic site leasing business, excellent services and cost control initiatives are likely to drive SBA Communications' (SBAC) fourth-quarter earnings.
- Zacks•2 days ago
What's in Store for Telefonica Brasil (VIV) in Q4 Earnings?
Telefonica Brasil's (VIV) fourth-quarter earnings are likely to benefit from its asset base and solid position in key high-value segments.
- Markit•12 days ago
See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
Theravance Biopharma Inc NASDAQ NMS:TBPHView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for TBPH with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding TBPH totaled $2.29 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- American City Business Journals•21 days ago
Why are deep-pocketed biotechs cutting hundreds of jobs?
Biotech companies' reasons differ for 600 job cuts over the past few months, but the numbers are jarring for an industry at the intersection of a strong cash position and groundbreaking science.
- PR Newswire•23 days ago
Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
DUBLIN, Jan. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a registrational Phase 3 clinical trial of ampreloxetine (TD-9855) in patients with symptomatic neurogenic orthostatic hypotension (nOH). Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor (NRI) in development for the treatment of patients with symptomatic nOH.
- Thomson Reuters StreetEvents•24 days ago
Edited Transcript of TBPH earnings conference call or presentation 6-Nov-18 10:00pm GMT
Q3 2018 Theravance Biopharma Inc Earnings Call
- American City Business Journals•28 days ago
With $500M in reserve, biotech cuts 49 jobs to focus on maturing drug pipeline
Looking long term, the company says, it cuts 49 jobs as it pushes multiple programs deeper into clinical trials.
- Simply Wall St.•last month
Should You Worry About Theravance Biopharma, Inc.’s (NASDAQ:TBPH) CEO Pay Cheque?
Rick Winningham has been the CEO of Theravance Biopharma, Inc. (NASDAQ:TBPH) since 2014. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will Read More...
- PR Newswire•last month
Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities
DUBLIN, Jan. 7, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced a reduction in workforce to align with its focus on continued execution of key strategic programs, and advancement of selected late-stage research programs toward clinical development. Theravance Biopharma will reduce its overall headcount by approximately 50 individuals, with affected employees primarily focused on early research or the infrastructure in support of VIBATIV® (telavancin). VIBATIV is a marketed antibiotic recently sold by the Company to Cumberland Pharmaceuticals, Inc.
- PR Newswire•3 months ago
Theravance Biopharma to Highlight Innovative Early Research and Clinical Development at R&D Day on December 12 in New York
DUBLIN, Dec. 4, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") will host an R&D Day from 12:00 p.m. ET to 3:00 p.m. ET on Wednesday, December 12, 2018, in New York City. Theravance Biopharma management and R&D teams will provide an overview of the Company's research and development strategy, plus clinical programs and emerging research projects in therapeutic areas such as inflammatory intestinal diseases, autonomic disorders, severe asthma, lung transplant rejection, idiopathic pulmonary fibrosis, and diabetic macular edema.
- PR Newswire•3 months ago
Theravance Biopharma Announces Closing of Private Placement of $250 Million of 9% Non-Recourse Notes
DUBLIN, Dec. 3, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" and together with its subsidiaries, the "Company") today announced the closing of a private placement of $250 million of non-recourse PhaRMASM 9% fixed rate term notes. The notes are secured by a portion of the future payments the Company expects to receive related to royalties due on net sales of Trelegy Ellipta. The Company intends to use the net proceeds from this transaction to support continued execution of its key strategic programs.
- Zacks•3 months ago
Theravance Pipeline Strong, Plans Yupelri Launch by Year End
Theravance (TBPH) plans to launch its newly approved COPD drug, Yupelri, before the end of 2018. However, sole dependence on Yupelri for revenues is a concern.
- Zacks•3 months ago
Theravance's Respiratory Disease JAK Inhibitor Enters Phase I
Theravance (TBPH) doses the first patient in a phase I study on novel JAK inhibitor, TD-8236, for treating serious respiratory diseases.
- PR Newswire•3 months ago
Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor
DUBLIN, Nov. 27, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first subject in a Phase 1 clinical trial of TD-8236, a novel, inhaled, lung-selective pan-Janus kinase (JAK) inhibitor which has demonstrated potency in preclinical assessments. The Company is developing TD-8236 as an investigational compound with the potential to treat a range of serious respiratory diseases. TD-8236 is an internally-discovered JAK inhibitor that has demonstrated a high affinity and selectivity for each of the JAK family enzymes (JAK1, JAK2, JAK3 and TYK2).
- Zacks•3 months ago
Theravance JAK Inhibitor Enters Phase II for Crohn's Disease
Theravance (TBPH) doses the first patient in a phase II Crohn's disease study on JAK inhibitor, TD-1473.
- Investor's Business Daily•3 months ago
IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses
Innoviva is the IBD Stock Of The Day as the biotech stock flirts with a breakout amid new uses for its GlaxoSmithKline-partnered medicines. Innoviva has several royalty deals with Glaxo.
- PR Newswire•3 months ago
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease
DUBLIN, Nov. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with Crohn's disease. TD-1473 is a novel, potent, orally administered and gut-selective pan-Janus kinase (JAK) inhibitor in development as a treatment for multiple inflammatory intestinal diseases.
